Bleeding Disorder Testing Market Report 2024

The bleeding disorder testing market size has grown strongly in recent years. It will grow from $13.92 billion in 2023 to $14.99 billion in 2024 at a compound annual growth rate (CAGR) of 7.7%. The growth observed in the historical period can be linked to the rising incidence of bleeding disorders, greater investment in research and development, an increasing number of specialized clinics, higher demand for early diagnosis, and a growing volume of clinical trials.

The bleeding disorder testing market size is expected to see strong growth in the next few years. It will grow to $20.4 billion in 2028 at a compound annual growth rate (CAGR) of 8%. The anticipated growth during the forecast period can be attributed to the rising incidence of hemophilia, growing awareness of bleeding disorder symptoms, increased investment in diagnostic research, higher global healthcare expenditure, and a growing prevalence of rare bleeding disorders. Key trends for the forecast period include advancements in technology, the integration of artificial intelligence, the rise of personalized medicine, the expansion of telemedicine services, and the availability of home-based testing kits.

The increasing number of clinical trials is anticipated to boost the growth of the bleeding disorder testing market in the coming years. Clinical trials, which are research studies that evaluate the safety and effectiveness of new medical treatments, therapies, medicines, or technologies in humans, are on the rise. This increase is driven by advancements in medical research, growing investment in healthcare innovation, and the rising demand for new treatments and therapies. In these trials, bleeding disorder testing is crucial for assessing the efficacy and safety of new medicines and therapies for bleeding disorders, evaluating their ability to manage or correct clotting abnormalities, and monitoring patient responses to ensure optimal dosing and effectiveness. For example, according to ClinicalTrials.gov, a US-based clinical trial registry, approximately 477,228 clinical trials were registered by the end of 2023, up from 437,507 in 2022. Thus, the growing number of clinical trials is propelling the bleeding disorder testing market's expansion.

Leading companies in the bleeding disorder testing market are focusing on developing innovative products, such as gene therapy for Hemophilia B, to provide long-term solutions, cure genetic bleeding disorders, improve treatment outcomes, and broaden their market presence. Hemophilia B, characterized by a deficiency of clotting factor IX necessary for proper blood coagulation, is a specific type of bleeding disorder. Gene therapy for Hemophilia B is an emerging treatment that aims to offer a long-term solution by addressing the underlying genetic defect causing the condition. For instance, in February 2023, CSL Limited, an Australia-based biotechnology company, received conditional marketing authorization (CMA) from the European Commission for HEMGENIX, the first and only one-time gene therapy for treating severe and moderately severe Hemophilia B. This innovative treatment aims to provide long-lasting efficacy, potentially reducing or eliminating the need for regular factor replacement therapy and significantly altering the standard of care for Hemophilia B patients.

In May 2022, Sema4, a US-based company specializing in genetic testing and data-driven patient insights, acquired GeneDx, LLC for $150 million. This acquisition aims to enhance Sema4's genetic testing capabilities by integrating GeneDx’s expertise in genetic diagnostics for rare and inherited disorders, including bleeding disorders. GeneDx LLC, also based in the US, offers testing related to bleeding disorders as part of its comprehensive genetic diagnostic services.

Major companies operating in the bleeding disorder testing market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Bayer AG, Takeda Pharmaceutical Company Limited, Novo Nordisk A/S, Siemens Healthcare GmbH, Baxter International Inc., CSL Limited, Octapharma AG, HORIBA Ltd., Haemonetics Corporation, Diagnostica Stago S.A.S., Sekisui Diagnostics LLC, Helena Laboratories Corporation, LFB Group, Sysmex Inostics GmbH, Medexus Pharmaceuticals Inc., Precision Biologics Inc., Corgenix Inc., Diapharma Group Inc., Hyphen BioMed, Hema Biologics LLC.

North America was the largest region in the bleeding disorder testing market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the bleeding disorder testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the bleeding disorder testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Bleeding disorder testing encompasses a variety of diagnostic methods aimed at assessing the function and composition of blood to detect abnormalities associated with bleeding disorders. These tests evaluate clotting ability, platelet function, and specific deficiencies or dysfunctions of clotting factors.

The primary product categories for bleeding disorder testing are reagents and consumables, as well as instruments. The reagents and consumables segment includes the chemical substances, materials, and disposable items utilized in the diagnosis and analysis of bleeding disorders. This category features test kits, reagents, and other necessary supplies for performing these tests. Common indications for these tests include hemophilia A, hemophilia B, von Willebrand disease, idiopathic thrombocytopenic purpura, among others. Treatments generally involve factor replacement therapy and drug therapy, and the tests are used by various end-users, such as hospitals, clinics, and diagnostic centers.

The bleeding disorder testing market research report is one of a series of new reports that provides bleeding disorder testing market statistics, including bleeding disorder testing industry global market size, regional shares, competitors with a bleeding disorder testing market share, detailed bleeding disorder testing market segments, market trends, and opportunities, and any further data you may need to thrive in the bleeding disorder testing industry. This bleeding disorder testing research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The bleeding disorder testing market consists of revenues earned by entities by providing services such as complete blood count (CBC), prothrombin time (PT), activated partial thromboplastin time (aPTT), and genetic testing. The market value includes the value of related goods sold by the service provider or included within the service offering. The bleeding disorder testing market also includes sales of coagulation analyzers, platelet aggregation analyzers, blood collection devices, genetic testing kits, and bleeding time test kits. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.